HRP20191070T1 - Intervencije na bazi angiopoietina za liječenje cerebralne malarije - Google Patents
Intervencije na bazi angiopoietina za liječenje cerebralne malarije Download PDFInfo
- Publication number
- HRP20191070T1 HRP20191070T1 HRP20191070TT HRP20191070T HRP20191070T1 HR P20191070 T1 HRP20191070 T1 HR P20191070T1 HR P20191070T T HRP20191070T T HR P20191070TT HR P20191070 T HRP20191070 T HR P20191070T HR P20191070 T1 HRP20191070 T1 HR P20191070T1
- Authority
- HR
- Croatia
- Prior art keywords
- angiopoietin
- preparation
- modified angiopoietin
- modified
- administered
- Prior art date
Links
- 108010009906 Angiopoietins Proteins 0.000 title claims 18
- 102000009840 Angiopoietins Human genes 0.000 title claims 18
- 206010063094 Cerebral malaria Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 16
- 238000002360 preparation method Methods 0.000 claims 12
- 102100034594 Angiopoietin-1 Human genes 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 108010048154 Angiopoietin-1 Proteins 0.000 claims 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 4
- 102000008946 Fibrinogen Human genes 0.000 claims 3
- 108010049003 Fibrinogen Proteins 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 229940012952 fibrinogen Drugs 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- 229960004991 artesunate Drugs 0.000 claims 2
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 230000011514 reflex Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 1
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 108010024212 E-Selectin Proteins 0.000 claims 1
- 102100023471 E-selectin Human genes 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000009182 Parasitemia Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 206010041660 Splenomegaly Diseases 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229960004191 artemisinin Drugs 0.000 claims 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 1
- 229930101531 artemisinin Natural products 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 230000001723 fibrinogenic effect Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 230000009919 sequestration Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Farmaceutski pripravak koji sadrži terapijski učinkovitu količinu modificiranog proteina angiopoietina za primjenu u metodi za liječenje, sprječavanje ili ublažavanje najmanje jednog simptoma, indikacije ili komplikacije cerebralne malarije, pri čemu se spomenuta metoda sastoji od primjene pripravka kod ispitanika kojemu je isti potreban, naznačen time, što modificirani angiopoietin sadrži fuzijski protein koji sadrži najmanje jednu fibrinogensku domenu angiopoietina-1 spojenu s imunoglobulinskim Fc fragmentom.
2. Pripravak za primjenu u metodi prema patentnom zahtjevu 1, naznačen time, što je najmanje jedan simptom, indikacija ili komplikacija odabrana iz grupe koja se sastoji od groznice, glavobolje i mijalgije popraćene pospanošću, konfuzijom, vaskularnim propuštanjem, gubitkom integriteta krvno-moždane barijere, povišenom razinom endotelnog markera u krvi, opcionalno odabrana iz grupe koja se sastoji od Ang1, Ang2, Tie2, vWF, ICAM-1, E-selektina i VCAM-1, sekvestracije parazitiranih eritrocita u mozgu, narušene ravnoteže ili koordinacije, motoričkog oštećenja, splenomegalije, gubitka refleksa i samoodržanja, nedostatka higijene, akutne ozljede pluća, konvulzija, napadaja, kome i smrti.
3. Pripravak za primjenu u metodi prema patentnom zahtjevu 1 ili 2, naznačen time, što:
(a) modificirani angiopoietin se primjenjuje u dozi od 5 do 50 mg/kg tjelesne težine subjekta, opcionalno naznačen time, što se modificirani angiopoietin primjenjuje u dozi od 15 mg/kg tjelesne težine subjekta; i/ili
(b) modificirani angiopoietin se primjenjuje supkutano; i/ili
(c) modificirani angiopoietin se primjenjuje u kombinaciji s drugim terapijskim sredstvom; i/ili
(d) modificirani angiopoietin se primjenjuje u kombinaciji s drugim terapijskim sredstvom, a drugo terapijsko sredstvo je odabrano iz grupe koja se sastoji od artemisinina, kinina i njihove varijante ili derivata, opcionalno naznačen time, što je drugo terapijsko sredstvo artesunat.
4. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 3, naznačen time, što primjena modificiranog angiopoietina povećava preživljenje.
5. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 3, naznačen time, što modificirani angiopoietin štiti integritet krvno-moždane barijere.
6. Farmaceutski pripravak koji sadrži terapijski učinkovitu količinu modificiranog proteina angiopoietina za primjenu u metodi za sprječavanje teške cerebralne malarije kod subjekta zaraženog rodom Plasmodium, pri čemu se metoda sastoji od: (a) odabira subjekta s parazitemijom većom od 0,1 %; i (b) primjene farmaceutskog pripravka kod subjekta kojemu je isti potreban, naznačen time, što modificirani angiopoietin sadrži fuzijski protein koji sadrži najmanje jednu fibrinogensku domenu angiopoietina-1 spojenu s imunoglobulinskim Fc fragmentom.
7. Pripravak za primjenu u metodi prema patentnom zahtjevu 6, naznačen time, što primjena modificiranog angiopoietina sprječava najmanje jednu indikaciju odabranu iz grupe koja se sastoji od neurološkog oštećenja i vaskularnog propuštanja, opcionalno naznačen time, što je najmanje jedna indikacija neurološkog oštećenja odabrana iz grupe koja se sastoji od narušene ravnoteže ili koordinacije, motoričkog oštećenja, gubitka refleksa i samoodržanja, dugoročne neurokognitivne ozljede i oštećenja, narušenog pamćenja, afektivnih poremećaja, nedostatka higijene, konvulzija i napadaja.
8. Pripravak za primjenu u metodi prema patentnom zahtjevu 6 ili 7, naznačen time, što primjena modificiranog angiopoietina sprječava gubitak integriteta krvno-moždane barijere.
9. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 6 do 8, naznačen time, što:
(a) modificirani angiopoietin se primjenjuje u dozi od 15 mg/kg tjelesne težine subjekta; i/ili
(b) modificirani angiopoietin se primjenjuje supkutano; i/ili
(c) modificirani angiopoietin se primjenjuje u kombinaciji s drugim terapijskim sredstvom, opcionalno naznačen time, što je drugo terapijsko sredstvo artesunat.
10. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 9, naznačen time, što fuzijski protein sadrži prvu fibrinogensku domenu angiopoietina-1 spojenu na svom C-terminusu s N-terminusom Fc fragmenta i Fc fragment na svom C-terminusu spojen s N-terminusom druge fibrinogenske domene angiopoietina-1.
11. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 10, naznačen time, što je modificirani angiopoietin AngF1-Fc-F1.
12. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 11, naznačen time, što Fc fragment sadrži Fc domenu IgG-a.
13. Pripravak za primjenu u metodi prema patentnom zahtjevu 12, naznačen time, što je Fc domena IgG-a Fc domena humanog IgG1.
14. Pripravak za primjenu u metodi prema bilo kojem patentnom zahtjevu od 1 do 13, naznačen time, što se modificirani angiopoietin-1 sastoji od aminokiselinske sekvence SEQ ID NO:2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898539P | 2013-11-01 | 2013-11-01 | |
| US201462040514P | 2014-08-22 | 2014-08-22 | |
| EP14800207.4A EP3062811B1 (en) | 2013-11-01 | 2014-10-31 | Angiopoietin-based interventions for treating cerebral malaria |
| PCT/US2014/063347 WO2015066426A2 (en) | 2013-11-01 | 2014-10-31 | Angiopoietin-based interventions for treating cerebral malaria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191070T1 true HRP20191070T1 (hr) | 2019-09-20 |
Family
ID=51932597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191070TT HRP20191070T1 (hr) | 2013-11-01 | 2019-06-13 | Intervencije na bazi angiopoietina za liječenje cerebralne malarije |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9592271B2 (hr) |
| EP (1) | EP3062811B1 (hr) |
| JP (1) | JP2016537416A (hr) |
| KR (1) | KR20160099085A (hr) |
| CN (1) | CN105873599A (hr) |
| AU (1) | AU2014342162B2 (hr) |
| CA (1) | CA2928852A1 (hr) |
| CY (1) | CY1121710T1 (hr) |
| DK (1) | DK3062811T3 (hr) |
| ES (1) | ES2727532T3 (hr) |
| HR (1) | HRP20191070T1 (hr) |
| HU (1) | HUE044660T2 (hr) |
| LT (1) | LT3062811T (hr) |
| MX (1) | MX2016005446A (hr) |
| PL (1) | PL3062811T3 (hr) |
| PT (1) | PT3062811T (hr) |
| RS (1) | RS59000B1 (hr) |
| SI (1) | SI3062811T1 (hr) |
| WO (1) | WO2015066426A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110122881A (ko) | 2006-04-07 | 2011-11-11 | 워너 칠콧 컴퍼니 엘엘씨 | 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도 |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| JP5536113B2 (ja) | 2009-07-06 | 2014-07-02 | アケビア セラピューティクス インコーポレイテッド | がん細胞の転移を予防するための化合物、組成物および方法 |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| PT3062811T (pt) | 2013-11-01 | 2019-06-11 | Regeneron Pharma | Intervenções à base de angiopoietina para o tratamento da malária cerebral |
| JP6483148B2 (ja) | 2014-03-14 | 2019-03-13 | エアーピオ セラピューティクス インコーポレイテッド | ＨＰＴＰ−β阻害剤 |
| CN108290057A (zh) | 2015-09-23 | 2018-07-17 | 爱尔皮奥治疗有限公司 | 用tie-2的激活剂治疗眼内压的方法 |
| WO2017079556A1 (en) * | 2015-11-06 | 2017-05-11 | Regeneron Pharmaceuticals, Inc. | Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders |
| ES2962812T3 (es) | 2018-10-29 | 2024-03-21 | Ottawa Hospital Res Inst | Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos |
| WO2020159444A1 (en) * | 2019-01-30 | 2020-08-06 | Agency For Science, Technology And Research | Use of igfbp7 for treating malaria |
| JP2022530657A (ja) | 2019-04-29 | 2022-06-30 | アイポイント ファーマシューティカルズ， インコーポレイテッド | シュレム管を標的とするＴｉｅ－２活性化物質 |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
| JP2023515827A (ja) * | 2020-02-28 | 2023-04-14 | ノースウェスタン ユニバーシティ | 房水流出を高め、眼圧を減少させる方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1025193A (en) | 1911-03-01 | 1912-05-07 | Oliver Jefferson Kennedy | Foldable holder for writing-pads. |
| JP4493854B2 (ja) | 1998-12-23 | 2010-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | リガンドの生物学的活性を増強する方法 |
| EP2457578B1 (en) * | 2004-09-28 | 2015-08-19 | Aprogen, Inc. | Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction |
| US20070154482A1 (en) | 2005-09-12 | 2007-07-05 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| WO2011093851A1 (en) * | 2010-01-26 | 2011-08-04 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for treatment of vascular hyperpermeability |
| US9017670B2 (en) * | 2011-08-19 | 2015-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-Tie2 antibodies and uses thereof |
| PT3062811T (pt) | 2013-11-01 | 2019-06-11 | Regeneron Pharma | Intervenções à base de angiopoietina para o tratamento da malária cerebral |
-
2014
- 2014-10-31 PT PT14800207T patent/PT3062811T/pt unknown
- 2014-10-31 PL PL14800207T patent/PL3062811T3/pl unknown
- 2014-10-31 EP EP14800207.4A patent/EP3062811B1/en active Active
- 2014-10-31 LT LTEP14800207.4T patent/LT3062811T/lt unknown
- 2014-10-31 WO PCT/US2014/063347 patent/WO2015066426A2/en active Application Filing
- 2014-10-31 KR KR1020167014463A patent/KR20160099085A/ko not_active Application Discontinuation
- 2014-10-31 SI SI201431185T patent/SI3062811T1/sl unknown
- 2014-10-31 CA CA2928852A patent/CA2928852A1/en not_active Abandoned
- 2014-10-31 ES ES14800207T patent/ES2727532T3/es active Active
- 2014-10-31 AU AU2014342162A patent/AU2014342162B2/en not_active Ceased
- 2014-10-31 RS RS20190841A patent/RS59000B1/sr unknown
- 2014-10-31 MX MX2016005446A patent/MX2016005446A/es active IP Right Grant
- 2014-10-31 JP JP2016552251A patent/JP2016537416A/ja active Pending
- 2014-10-31 US US14/529,677 patent/US9592271B2/en active Active
- 2014-10-31 CN CN201480058778.6A patent/CN105873599A/zh active Pending
- 2014-10-31 DK DK14800207.4T patent/DK3062811T3/da active
- 2014-10-31 HU HUE14800207 patent/HUE044660T2/hu unknown
-
2017
- 2017-01-25 US US15/414,925 patent/US9968653B2/en not_active Expired - Fee Related
-
2018
- 2018-04-10 US US15/949,472 patent/US10251938B2/en not_active Expired - Fee Related
-
2019
- 2019-02-21 US US16/282,199 patent/US10525106B2/en not_active Expired - Fee Related
- 2019-05-06 CY CY20191100475T patent/CY1121710T1/el unknown
- 2019-06-13 HR HRP20191070TT patent/HRP20191070T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3062811T3 (da) | 2019-05-13 |
| PL3062811T3 (pl) | 2019-10-31 |
| US10251938B2 (en) | 2019-04-09 |
| PT3062811T (pt) | 2019-06-11 |
| JP2016537416A (ja) | 2016-12-01 |
| US20160045566A1 (en) | 2016-02-18 |
| RS59000B1 (sr) | 2019-08-30 |
| LT3062811T (lt) | 2019-05-10 |
| US10525106B2 (en) | 2020-01-07 |
| US9592271B2 (en) | 2017-03-14 |
| SI3062811T1 (sl) | 2020-07-31 |
| CN105873599A (zh) | 2016-08-17 |
| US9968653B2 (en) | 2018-05-15 |
| AU2014342162B2 (en) | 2020-01-02 |
| US20190175699A1 (en) | 2019-06-13 |
| EP3062811B1 (en) | 2019-04-03 |
| MX2016005446A (es) | 2017-01-05 |
| US20170136090A1 (en) | 2017-05-18 |
| WO2015066426A3 (en) | 2015-07-23 |
| KR20160099085A (ko) | 2016-08-19 |
| ES2727532T3 (es) | 2019-10-16 |
| WO2015066426A2 (en) | 2015-05-07 |
| CY1121710T1 (el) | 2020-07-31 |
| CA2928852A1 (en) | 2015-05-07 |
| US20180228870A1 (en) | 2018-08-16 |
| EP3062811A2 (en) | 2016-09-07 |
| HUE044660T2 (hu) | 2019-11-28 |
| AU2014342162A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191070T1 (hr) | Intervencije na bazi angiopoietina za liječenje cerebralne malarije | |
| ES2601400T3 (es) | Inmunoglobulinas caninas terapéuticas y métodos de uso de las mismas | |
| ES2897453T3 (es) | Aplicación de R-ketamina y sal de la misma como productos farmacéuticos | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| ES2762179T3 (es) | Terapia de combinación de inmunocitocinas | |
| RU2011104705A (ru) | Фактор фон виллебранда или фактор viii и фактор фон виллебранда для лечения коагулопатии, индуцированной ингибиторами тромбоцитов | |
| BR112013031198A2 (pt) | "anticorpo de ligação à c5ar, seu uso no tratamento de doenças imunológicas e composição farmacêutica que o compreende" | |
| BR112021013415A2 (pt) | Proteínas de fusão multifuncionais e usos das mesmas | |
| US20230255902A1 (en) | Cannabinoid formulations and dosage | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения | |
| BR112022010360A2 (pt) | Fármacos conjugados de polietilenoglicol ou um sal farmaceuticamente aceitável dos mesmos, intermediários e métodos para preparar os ditos fármacos, composição farmacêutica compreendendo os mesmos e uso terapêutico dos mesmos | |
| Badoiu et al. | Clinical Variant of Guillain–Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine | |
| AU2018284219A1 (en) | Hydrochloride salts of C5a receptor agonist peptides | |
| WO2015139020A2 (en) | Vaccine compositions and methods for restoring nkg2d pathway function against cancers | |
| US8460676B2 (en) | Composition comprising VLP and amyloid beta peptide | |
| Wang et al. | Immunotherapy for Alzheimer's disease | |
| EP3813869B1 (en) | Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation | |
| AR108681A1 (es) | Proteínas de fusión para oftalmología con retención ocular aumentada | |
| WO2013108056A1 (es) | Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares | |
| JP2019511515A5 (hr) | ||
| ES2864350T3 (es) | Pautas posológicas para uso con inhibidores de PCSK9 | |
| TH147858A (th) | การใช้สารอนุพันธ์แซลโมเนลลา แฟลกเจลลินในการเตรียมยาสำหรับการป้องกันและ การบำบัดโรคลำไส้อักเสบ | |
| EA030763B1 (ru) | Комбинация адреналина с антидепрессантом для применения в лечении шоков | |
| Franco-Paredes et al. | Reply to Newton et al | |
| TH1401006878A (th) | รีคอมบิแนนท์ อะดีโน-แอสโซซิเอเทดไวรัส (rAAV) เว็คเตอร์สำหรับใช้ในการบำบัดรักษาโรคการสร้างหลอดเลือดใหม่ของตาในผู้ป่วย ที่เคยได้รับสารยับยั้ง VEGF |